MX2015013155A - Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. - Google Patents
Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.Info
- Publication number
- MX2015013155A MX2015013155A MX2015013155A MX2015013155A MX2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrandrine
- pharmaceutical formulations
- family
- formulations
- tetrandrine family
- Prior art date
Links
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 title abstract 7
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical compound Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792849P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/021195 WO2014149848A1 (en) | 2013-03-15 | 2014-03-06 | Tetrandrine family pharmaceutical formulations and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013155A true MX2015013155A (es) | 2016-04-04 |
Family
ID=51529969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013155A MX2015013155A (es) | 2013-03-15 | 2014-03-06 | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9517234B2 (https=) |
| EP (1) | EP2968310A4 (https=) |
| JP (1) | JP2016512818A (https=) |
| KR (1) | KR20150142691A (https=) |
| CN (1) | CN105358149A (https=) |
| MX (1) | MX2015013155A (https=) |
| WO (1) | WO2014149848A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576077B2 (en) | 2015-03-23 | 2020-03-03 | Southwest Research Institute | Pharmaceutical salt forms of Cepharanthine and Tetrandrine |
| CN107260694A (zh) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂 |
| CN112402419B (zh) * | 2019-08-23 | 2023-12-08 | 华东理工大学 | 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用 |
| CN111675717B (zh) * | 2020-06-21 | 2023-04-07 | 兰州理工大学 | 粉防己单体化合物及其提取方法和用途 |
| US20230338362A1 (en) * | 2020-09-17 | 2023-10-26 | Iaterion, Inc. | Methods and compositions for treating viral infections |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN114159438B (zh) * | 2021-11-30 | 2023-07-18 | 首都医科大学附属北京安定医院 | 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4569852A (en) * | 1983-08-23 | 1986-02-11 | Warner-Lambert Company | Maintenance of flavor intensity in pressed tablets |
| JPH0678232B2 (ja) * | 1986-03-07 | 1994-10-05 | 株式会社ツムラ | アンジオテンシンｉ転換酵素阻害剤 |
| JPH0678231B2 (ja) * | 1986-03-08 | 1994-10-05 | 株式会社ツムラ | 血液粘度低下剤 |
| JPH0733388B2 (ja) * | 1987-01-22 | 1995-04-12 | 株式会社ツムラ | 新規アルカロイド |
| JPH02243627A (ja) * | 1989-03-16 | 1990-09-27 | Tsumura & Co | 狭心症治療薬 |
| US6911454B1 (en) | 1989-09-28 | 2005-06-28 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant disease |
| US5025020A (en) | 1989-09-28 | 1991-06-18 | Cancer Biologics Of America, Inc. | Use of tetrandrine and its derivatives to treat malaria |
| US5332747A (en) | 1989-09-28 | 1994-07-26 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells |
| JPH0499723A (ja) * | 1990-08-17 | 1992-03-31 | Kaken Shiyouyaku Kk | ウイルス・ゲノム不活化剤 |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5627195A (en) * | 1995-04-11 | 1997-05-06 | Massachusetts Eye And Ear Infirmary | Treatment for ocular inflammation |
| US6218541B1 (en) * | 1999-06-28 | 2001-04-17 | Cba, International, Inc. | Method for extracting bisbenzylisoquinolines |
| ATE283048T1 (de) * | 1999-12-08 | 2004-12-15 | Pharmacia Corp | Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt |
| US20050245559A1 (en) * | 2004-01-23 | 2005-11-03 | Koul Hari K | Treatment and prevention of prostate cancer |
| EP2069021A2 (en) * | 2006-08-04 | 2009-06-17 | AGI Therapeutics Research Limited | Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity |
| JP2011512416A (ja) * | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| EP2241561A1 (en) | 2009-04-16 | 2010-10-20 | Neuron Biopharma, S.A. | Neuroprotective, hypocholesterolemic and antiepileptic compound |
| US8609844B2 (en) | 2009-11-05 | 2013-12-17 | Cba Pharma, Inc. | Method for extracting and purifying bisbenzylisoquinolines |
| EP2491930A1 (en) * | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| JP2015531785A (ja) * | 2012-09-13 | 2015-11-05 | シービーエー・ファーマ・インコーポレイテッドＣｂａ Ｐｈａｒｍａ，Ｉｎｃ． | テトランドリン医薬製剤及び方法 |
| CN102898433B (zh) * | 2012-09-26 | 2015-04-15 | 中国医药研究开发中心有限公司 | 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途 |
| WO2014048377A1 (zh) * | 2012-09-28 | 2014-04-03 | 杭州本生药业有限公司 | 治疗肿瘤的组合药物及其应用 |
-
2014
- 2014-03-06 US US14/199,235 patent/US9517234B2/en active Active
- 2014-03-06 CN CN201480028296.6A patent/CN105358149A/zh active Pending
- 2014-03-06 MX MX2015013155A patent/MX2015013155A/es unknown
- 2014-03-06 WO PCT/US2014/021195 patent/WO2014149848A1/en not_active Ceased
- 2014-03-06 KR KR1020157029740A patent/KR20150142691A/ko not_active Ceased
- 2014-03-06 JP JP2016500735A patent/JP2016512818A/ja active Pending
- 2014-03-06 EP EP14767576.3A patent/EP2968310A4/en not_active Withdrawn
-
2016
- 2016-11-08 US US15/346,022 patent/US10023584B2/en active Active
- 2016-11-08 US US15/346,054 patent/US20170050976A1/en not_active Abandoned
-
2018
- 2018-06-20 US US16/012,872 patent/US10815243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968310A4 (en) | 2017-01-11 |
| US10023584B2 (en) | 2018-07-17 |
| CN105358149A (zh) | 2016-02-24 |
| US9517234B2 (en) | 2016-12-13 |
| EP2968310A1 (en) | 2016-01-20 |
| US10815243B2 (en) | 2020-10-27 |
| US20170050976A1 (en) | 2017-02-23 |
| JP2016512818A (ja) | 2016-05-09 |
| WO2014149848A1 (en) | 2014-09-25 |
| KR20150142691A (ko) | 2015-12-22 |
| US20180298022A1 (en) | 2018-10-18 |
| US20170050975A1 (en) | 2017-02-23 |
| US20140275137A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590870A1 (ru) | АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| TN2014000356A1 (en) | Heterocyclyl compounds as mek inhibitors | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| SG10201900648SA (en) | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide | |
| IN2014DN09434A (https=) | ||
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| TN2016000006A1 (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| WO2014106825A3 (en) | Methods and devices for identifying improper medical reporting | |
| MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
| IN2013MU00711A (https=) | ||
| EP4364741A3 (en) | Polymorphic form of tg02 | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| EA201600318A1 (ru) | Циклические тиеноурацилкарбоксамиды и их применение | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| PH12017501071B1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. |